CASPAR (Alliance A031902): A randomized, phase III trial of enzalutamide (ENZ) with rucaparib (RUCA)/placebo (PBO) as a novel therapy in first-line metastatic castration-resistant prostate cancer (mCRPC).

Arpit Rao,Charles J. Ryan,David J. VanderWeele,Glenn Heller,Lionel D. Lewis,Colleen Watt,Ronald C. Chen,Robert L. Grubb,Olwen Hahn,Himisha Beltran,Michael J. Morris

CASPAR (Alliance A031902): A randomized, phase III trial of enzalutamide (ENZ) with rucaparib (RUCA)/placebo (PBO) as a novel therapy in first-line metastatic castration-resistant prostate cancer (mCRPC).

2021

Arpit Rao
Charles J. Ryan
David J. VanderWeele
Glenn Heller
Lionel D. Lewis
Colleen Watt
Ronald C. Chen
Robert L. Grubb
Olwen Hahn
Himisha Beltran
Michael J. Morris

TPS181Background: Treatment with novel antiandrogens (NAA) and androgen deprivation therapy prolongs life in men with mCRPC but approximately 40% patients (pts) have radiographic progression within...

Keywords:

Oncology
Rucaparib
Prostate cancer
Placebo
Antiandrogens
castration resistant
Androgen deprivation therapy
Medicine
first line
Internal medicine
Enzalutamide

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations